JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

TransMedics Group Inc

Gesloten

SectorGezondheidszorg

130.6 2.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

128.42

Max

134.02

Belangrijke statistieken

By Trading Economics

Inkomsten

9.2M

35M

Verkoop

14M

157M

K/W

Sectorgemiddelde

59.064

37.461

Winstmarge

22.181

Werknemers

728

EBITDA

10M

46M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+12.09% upside

Dividenden

By Dow Jones

Volgende Winsten

29 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

527M

4.1B

Vorige openingsprijs

128.5

Vorige sluitingsprijs

130.6

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

TransMedics Group Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 aug 2025, 19:15 UTC

Belangrijke Marktbewegers

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Peer Vergelijking

Prijswijziging

TransMedics Group Inc Prognose

Koersdoel

By TipRanks

12.09% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 144.5 USD  12.09%

Hoogste 170 USD

Laagste 115 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor TransMedics Group Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

9

Buy

2

Hold

0

Sell

Technische score

By Trading Central

92.43 / 94.18Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat